Scholar Rock Holding Corp's stock soared 5.80% in pre-market trading on Tuesday, following the release of its fourth quarter and full year 2025 financial results alongside several significant business updates.

The biopharmaceutical company reported a Q4 net loss of $0.88 per share, which was slightly better than the FactSet consensus estimate of a $0.89 loss. More importantly, the company announced it secured up to $550 million in non-dilutive capital to support the commercialization of its lead candidate, apitegromab, and advance its pipeline.

Investors reacted positively to the constructive regulatory update, as the company stated its meeting with the FDA regarding the Catalent Indiana facility required no additional corrective actions, supporting its plans to resubmit the Biologics License Application (BLA) for apitegromab. The company anticipates U.S. and European launches of the drug in 2026, pending regulatory approvals. Analyst sentiment remains bullish, with a median 12-month price target of $50.00, representing significant upside potential from recent levels.